THANK YOU FOR SUBSCRIBING
The funds gathered during the Series A financing round will accelerate the efforts of the company in developing a novel approach for attacking tumor cells and establishing long-lasting immunity.
FREMONT, CA: Rigontec, a German biopharmaceutical company, recently closed its Series A financing round with €4.8 million from Forbion Capital Partners and Sunstone Capital. The funding raised the total investment to €14.2 million, bolstering its efforts to develop RNA-based immunotherapeutics for cancer treatment. Rigontec’s investor base includes Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK, and High-Tech Gründerfonds (HTGF).
The funds will accelerate Rigontec’s lead drug candidates to clinical proof-of-concept studies, enabling the expansion of its proprietary RNA-sensing technology. The company is developing synthetics ligands of a new type of receptor from the innate immune system, Retinoic Acid Inducible Gene I (RIG-I) which can identify viral RNA. The elimination of the infected cells and the induction of immune memory can be achieved through RNA motifs activation RIG-I, thus enabling the successful treatment and prevention of the disease.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The compound RGT100 is a proprietary state-of-the-art product designed to target RIG-I and is being assessed for its potential in treating different cancer types. Rigontec’s breakthrough technology will potentially enable the development of antiviral therapeutics. It can facilitate the creation of pipeline candidates with gene silencing and inhibitory activities, thus expanding the applications of the new product in areas of oncology and viral infections.
Rigontec emerged from the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital of the University of Bonn, Germany, in the year 2014. The company was founded by Prof. Gunther Hartmann and Prof. Veit Hornung, globally renowned scientific prodigies specializing in the area of innate immune recognition of viral nucleic acids (RNA immune sensing) and discovered 3pRNA (5’triphosphate RNA) as the ligand for RIG-I.
The groundbreaking scientific work by Prof. Hartmann and Prof. Hornung has birthed a novel approach to induce anti-tumor immunity by mimicking viral infections. The process successfully induces immunity in the territory of the tumor. Consequently, Rigontec’s product holds great promise in delivering personalized cancer treatment.
The proprietary RIG-I platform has garnered much attention and interest from the pharmaceutical community. It will enable focused attacks on tumor cells by inducing immunogenic cell death. By forcing a change in the tumor microenvironment, it fosters anti-cancer immunity and establishes long-lasting systemic immune memory.
More in News